Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Just saw UniQure's stock getting absolutely hammered today - down like 42% after the FDA basically said nope to their AMT-130 gene therapy data. They were banking on Phase I/II study results to support approval for this Huntington's disease treatment, but regulators weren't convinced the external control comparison was enough. So now they're looking at running a full Phase III randomized double-blind study, which is... yeah, basically back to square one in terms of timeline. The CEO's talking about meeting with FDA again in Q2 to figure out next steps, but the market clearly didn't like hearing that AMT-130 won't be taking the shortcut they were hoping for. Biotech is brutal - one meeting with regulators and your stock gets cut in half. Anyone else watching this one?